Nuvectis Pharma (NVCT) Assets Average (2022 - 2026)
Nuvectis Pharma (NVCT) posted Assets Average of $28.6 million for Q1 2026, down 15.14% sequentially from $33.6 million in Q4 2025, and up 17.13% YoY from $24.4 million in Q1 2025.
Nuvectis Pharma (NVCT) Assets Average (2022 - 2026) Analysis & Trends
Nuvectis Pharma has reported Assets Average for 5 years, with the latest figure at $28.6 million in Q1 2026.
- Quarterly Assets Average rose 17.13% year-over-year to $28.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.6 million (up 17.13% YoY) and the FY2025 annual result came in at $25.2 million, up 33.14% from the prior year.
- Assets Average declined to $28.6 million in Q1 2026 per NVCT's latest filing, from $33.6 million in the prior quarter.
- Over five years, Assets Average peaked at $33.6 million in Q4 2025 and troughed at $12.1 million in Q1 2022.
- A 5-year average of $22.0 million and a median of $20.6 million in 2023 frame the typical range for Assets Average.
- The sharpest annual moves came in 2024 and 2025: Assets Average fell 24.57% in 2024, then soared 87.38% in 2025.
- Over 5 years, Assets Average stood at $22.6 million in 2022, then declined by 8.45% to $20.7 million in 2023, then declined by 13.35% to $18.0 million in 2024, then jumped by 87.38% to $33.6 million in 2025, then retreated by 15.14% to $28.6 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $28.6 million, $33.6 million, and $31.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | 23.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 23.89 Mn |
| Mar 31, 2026 | 28.55 Mn |
| Dec 31, 2025 | 33.65 Mn |
| Sep 30, 2025 | 31.30 Mn |
| Jun 30, 2025 | 28.58 Mn |
| Mar 31, 2025 | 24.38 Mn |
| Dec 31, 2024 | 17.96 Mn |
| Sep 30, 2024 | 17.80 Mn |
| Jun 30, 2024 | 19.01 Mn |
| Mar 31, 2024 | 19.45 Mn |
| Dec 31, 2023 | 20.72 Mn |
| Sep 30, 2023 | 23.60 Mn |
| Jun 30, 2023 | 20.57 Mn |
| Mar 31, 2023 | 18.31 Mn |
| Dec 31, 2022 | 22.64 Mn |
| Sep 30, 2022 | 19.55 Mn |
| Jun 30, 2022 | 15.93 Mn |
| Mar 31, 2022 | 12.14 Mn |